We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Global Regulator of Gene Transcription Identified as Potential Anticancer Drug Target

By LabMedica International staff writers
Posted on 14 Feb 2016
The enzyme MLL1 (histone-lysine N-methyltransferase 2A) was identified as a potential target for anticancer drugs after researchers found that its inhibition prevented tumor development by shutting down the DNA damage response mechanism and suppressed inflammation by blocking the activity of proliferation-promoting genes.

MLL is a histone methyltransferase deemed a positive global regulator of gene transcription. More...
This protein belongs to the group of histone-modifying enzymes and is involved in the epigenetic maintenance of transcriptional memory. Previous observations linked this transcription-associated methyltransferase and oncoprotein to the DNA damage response (DDR), which led investigators at the University of Pennsylvania (Philadelphia, USA) to examine the role of MLL1 in cancer development and in the appearance of age-related inflammation.

They reported in the February 1, 2016, issue of the journal Genes & Development that MLL1 displayed direct epigenetic control over pro-proliferative cell cycle genes. Inhibition of MLL1 repressed expression of pro-proliferative cell cycle regulators required for DNA replication and DDR activation, thus disabling age-related inflammation expression. However, these effects of MLL1 inhibition on age-related inflammation gene expression did not impair oncogene-induced senescence (OIS) and, abolished the ability of the age-related inflammation to enhance cancer cell proliferation. These results demonstrated that MLL1 inhibition may be a powerful and effective strategy for blocking cancerous growth through the direct epigenetic regulation of proliferation-promoting genes.

"Since tumor-promoting inflammation is one of the hallmarks of cancer, these findings suggest that MLL1 inhibitors may be highly potent anticancer drugs through both direct epigenetic effects on proliferation-promoting genes, as well as through the inhibition of inflammation in the tumor microenvironment," said first author Dr. Brian Capell, a medical fellow in epigenetics and dermatology at the University of Pennsylvania. "In cancer, this could be a potent one-two punch, by blocking both proliferation-promoting genes as well as the cancerous inflammation. One could imagine taking an MLL1 inhibitor as a primary treatment, but also as an adjuvant therapy to tamp down the rampant inflammation caused by drugs like chemotherapies."

Related Links:

University of Pennsylvania



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.